Insider Buying: Precipio, Inc. (NASDAQ:PRPO) Director Buys 20,000 Shares of Stock

Precipio, Inc. (NASDAQ:PRPO – Get Rating) Director Richard A. Sandberg bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 20th. The shares were acquired at an average cost of $0.78 per share, with a total value of $15,600.00. Following the completion of the purchase, the director now owns 40,846 shares of the company’s stock, valued at $31,859.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Precipio Stock Down 2.4 %

PRPO stock opened at $0.80 on Tuesday. Precipio, Inc. has a 12 month low of $0.47 and a 12 month high of $1.77. The firm has a market cap of $18.26 million, a PE ratio of -1.54 and a beta of 2.16. The firm has a 50 day simple moving average of $0.68 and a 200 day simple moving average of $0.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.68 and a quick ratio of 1.53.

Precipio (NASDAQ:PRPO – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($0.14) EPS for the quarter. Precipio had a negative net margin of 128.09% and a negative return on equity of 56.55%. The business had revenue of $2.22 million for the quarter.

Institutional Trading of Precipio

An institutional investor recently bought a new position in Precipio stock. Great Valley Advisor Group Inc. purchased a new stake in Precipio, Inc. (NASDAQ:PRPO – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,100 shares of the biotechnology company’s stock, valued at approximately $35,000. Great Valley Advisor Group Inc. owned approximately 0.15% of Precipio as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.62% of the company’s stock.

Precipio Company Profile

(Get Rating)

Precipio, Incis a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.